n=7; child n=2; adult n=11) and MDR1 expression in 61 pediatric liver samples. Intestinal expression of MDR1, MRP2 and OATP2B1 was determined in surgical small bowel samples (neonates n=15, infants n=3, adults n=14). Using real time RT-PCR, fetal and pediatric gene expression was determined relative to 18S rRNA (liver) and villin (intestines), and compared to adults using the 2 -∆∆Ct method. Hepatic expression of MRP2, OATP1B1 and OATP1B3 in all pediatric age groups was significantly lower than in adults. Hepatic MDR1 mRNA expression in fetuses, neonates and infants was significantly lower than in adults. Neonatal intestinal expressions of MDR1 and MRP2 were comparable to those in adults. Intestinal OATP2B1 expression in neonates was significantly higher than in adults. We provide new data that show organ-and transporter-dependent differences in hepatic and intestinal drug transporter expression in an age-dependent fashion. This suggests that substrate drug absorption mediated by these transporters may be subject to age-related variation in a transporter dependent pattern.
This article has not been copyedited and formatted. The final version may differ from this version. 
INTRODUCTION
Drug transporters are membrane-bound proteins whose primary function is to facilitate the trafficking of drugs and their metabolites across a biological membrane. Expressed in structural cells that compose the organs of importance to drug disposition, such as enterocytes and hepatocytes, they are involved in the active uptake and elimination of orally administered drugs. In adults, drug transporters are recognized as key determinants of variation in the pharmacokinetics of many drugs, as shown in studies using primary cell and ex vivo organ cultures as well as clinical studies (DeGorter et al., 2012) . In contrast, such data in children are scarce and clinical studies are absent (Chen et al., 2005; Fakhoury et al., 2005; Miki et al., 2005; Fukudo et al., 2006; Chen et al., 2008; Mizuno et al., 2013) .
Pharmacokinetics in children is known to be affected by developmental changes with age (Kearns et al., 2003) . Drug metabolizing enzyme activity, for example, changes significantly from fetal to adolescent age associated with alterations in metabolic clearance of many drugs (de Wildt, 2011) . Notably, hepatic and intestinal expression of cytochrome P450
(CYP) 3A4 shows a clear developmental pattern, and systemic clearance of midazolam, a known substrate of CYP3AA changes with age (Johnson et al., 2001; de Wildt et al., 2002; Leeder et al., 2005) . Similarly, compared to adults, differences in body composition and renal function in children affect drug tissue distribution and renal drug excretion, respectively.
As a consequence, it has become apparent that simply extrapolating drug doses from adults to children based on body weight is likely inaccurate due to lack of our understanding of age-dependent differences in the maturation of the drug absorption and elimination processes involved in drug disposition. As the expression of drug metabolizing enzymes appears to be age-related, it is also likely that this is the case for drug transporter expression.
Data from animal studies report occurrence of transporter-specific maturation (Klaassen and Aleksunes, 2010 
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(BCRP/ABCG2) were found to be expressed in fetal liver or intestine, but otherwise little is known on developmental patterns of individual drug transporters (Chen et al., 2008; Fakhoury et al., 2009; Sharma et al., 2013) . Systematic characterization of age-related differences in transporter expression will aid the selection of the most appropriate dose for substrate drugs in children.
In a first step towards elucidating the developmental changes, this study determined the gene expression of clinically relevant hepatic and intestinal drug transporters across the pediatric age range. We focused on transporters with well-defined roles in drug pharmacokinetics in adults (DeGorter et al., 2012) (Fig. 1) . These included the efflux carriers MDR1 and MRP2 in liver and intestine, and uptake carriers of the organic anion transporting polypeptide (OATP/SLCO) family including the liver-specific transporters OATP1B1 and OATP1B3, and OATP2B1 in the intestine.
This article has not been copyedited and formatted. The final version may differ from this version. Previously optimized primers were used (supplemental file) . Modified primers were used for villin and OATP2B1 (reverse primer only), and primer sequences were obtained via qPrimer Depot (http://primerdepot.nci.nih.gov/). After each PCR, a melting curve analysis was performed to confirm product specificity. Eukaryotic 18S rRNA was assessed as endogenous control with the use of a TaqMan VIC/MGB probe (4319413E, Applied Biosystems). Transporter transcript levels were normalized to18s rRNA, and relative expression was determined using the 2 -ΔΔCT method comparing pediatric samples to adult liver or intestine (calibrator samples) (Schmittgen and Livak, 2008) . The adult target gene value was determined by using the median of the adult Ct values.
For comparison, all 96 well plates analyzing liver samples included a specific liver control sample to normalize expression for the gene of interest and 18S rRNA, if appropriate.
Similarly, a specific intestinal sample was added to plates to normalize for the genes of interest, 18S rRNA and villin if appropriate.
Statistics
RESULTS

Sample characteristics
Characteristics of all samples are provided in Table 1 , 1992) . We show that MDR1 expression changes after birth with low mRNA expression until 12 months of age, thereupon increasing to adult levels. In a recent study, using a novel LC-MS-MS method to estimate protein expression, from 7 years onwards, MDR1 was stable up to 70 years of age in a cohort of more than 50 patients (Prasad et al., 2014) .
Low fetal MRP2 expression in humans has been reported earlier in two small studies (n=10, 14-20 weeks GA; and n=3, 20-21 weeks GA) (Chen et al., 2005; Sharma et al., 2013) .
In the latter, however, 2 of 5 control adult liver samples were from normal tissue in patients with hepatocellular carcinoma (HCC). Since organic cation transporter (OCT)1 expression has been shown to be lower in non-tumor HCC liver than healthy liver, a similar phenomenon with other transporters cannot be excluded (Schaeffeler et al., 2011) . Using immunohistochemical staining, distinct canalicular expression of MRP2 in adult liver was observed, but a fuzzier canalicular occurrence in fetal liver which may suggest immaturity of the localization pattern (Chen et al., 2005) . In addition, fetal human liver tissues obtained at 14 19 weeks GA showed higher MRP2 signal intensity than tissues obtained at 14 weeks (Cizkova et al., 2005) In our study, neonatal MRP2 gene expression was lower than in adults. From 7 years onwards, MRP2 protein expression was stable. (Prasad et al., 2013) .
The observed lower fetal OATP1B1 and OATP1B3 mRNA expression levels in the present study are also in line with human data of 3 fetal (21-23 weeks GA) and 3 adult livers (Sharma et al., 2013) . In our study, OATP1B1 and OATB1B3 expression was also low in neonates. In contrast, reported neonatal OATP1B1 and OATP1B3 protein expression (n=5), was similar in adults (Yanni et al., 2011) . In 80 human pediatric liver samples ranging from age 2 months to 12 years, OATP1B1 was low until 6 years of age, while OATP1B3 protein levels were high at birth, then rapidly decreased in the first year to then increase again from 8 years of age onwards to adult levels (Thomson et al., 2013) . From 7 years onwards, OATP1B1 and OATP1B3 protein expression was stable, with only genotype related to OATP1B1
abundance (Prasad et al., 2014) .
Ontogeny in intestinal transporters
We observed stable intestinal MDR1 expression from neonatal to adult age, which finding fills a gap between currently available fetal and pediatric data. Previously, fetal intestinal tissue obtained after induced abortion, showed no or minimal MDR1 mRNA expression in samples after 11, 13 and 14 weeks, but clear expression at 16 and 20 weeks gestational age (van Kalken et al., 1992) . Another study reported similar small intestinal MDR1 mRNA expression in fetuses (14 to 20 weeks gestational age), neonates and adults (Miki et al., 2005) . However, a limitation is the small sample size [n=5, n=12 (fetus plus neonates)] (van Kalken et al., 1992; Miki et al., 2005) . Stable MDR1 mRNA expression in children from one month to adulthood was shown in non-diseased duodenal biopsy and jejunal tissue from liver donor recipients (Fakhoury et al., 2005; Mizuno et al., 2013) . We also found stable intestinal MRP2 expression, but higher expression levels of OATP2B1 in neonates compared to adults.
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Transporter maturation observed in the present study likely reflects physiological roles of these transporters in organ development. Epigenetic mechanisms such as DNA methylation are thought to be involved in maturation of drug metabolizing enzymes. For example, DNA methylation seems to partly explain a developmental switch from expression of CYP3A7 to CYP3A4 in human fetal and adult liver (Kacevska et al., 2012) . Epigenetic mechanisms may be also involved in the developmental regulation of drug transporter expression, however studies are currently lacking.
Due to mediation by transcription factors (which in their turn can be induced by chemicals or pathological conditions) some transporters show relatively high whereas others show low expression (Klaassen and Aleksunes, 2010) . For example, expression of the steroid-and xenobiotic-sensing pregnane X receptor (PXR) was shown to correlate with intestinal BCRP, MRP2 and MDR1 mRNA in many different human tissues (e.g. intestine and liver) (Synold et al., 2001; Albermann et al., 2005; Miki et al., 2005) . We may further speculate that the ontogeny of transporters is a combined function of developmental changes, genetic heterogeneity, and exposure to substrates (drug or environmental) that induce or inhibit expression and/or activity. For example, CYP1A2 and CYP3A4 activity, assessed by phenotyping caffeine and dextromethorphan, respectively, was shown to be affected by the type of infant feeding (breast milk or formula) (Blake et al., 2006) . Dietary supplements in infant formula decreased MDR1 expression in colon cell cultures (Bebawy et al., 2009) . Moreover, the effect of feeding is more variable when a child's diet is expanded, as specific nutrients can influence MDR1 expression (Schwarz et al., 2005; Schwarz et al., 2007 ).
This study is one of the first exploratory studies characterizing developmental changes in hepatic and intestinal transporters. Some limitations of the data should be addressed. First, most fetal liver samples were obtained in the second trimester of gestation, thus results might not be representative for the entire range of gestational age. Second, the variation in fetal transporter mRNA expression may be partly due to the small number of samples 
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representing ages more distant from the median age. Given the small number per age group, the range of expression might not be representative for the entire population.
Third, all liver samples were collected within 24 hours after death, but the exact time is unknown. Still, RNA stability was minimized by RNA integrity determination.
Also, our samples may display disease-dependent variability in transporter expression.
Inflammation has been shown to affect drug metabolism and transport. Decreased midazolam clearance in critically ill children is likely a result of reduced CYP3A activity (Vet et al., 2012) . Inconsistency has been reported from studies assessing the effect of proinflammatory cytokines on intestinal MDR1 expression in vitro and in animal models, but suggest a trend towards decreased expression (Fernandez et al., 2004) . In children with
Crohn disease, MDR1 expression was higher in both inflamed and non-inflamed duodenal biopsies compared to healthy age-matched controls (Fakhoury et al., 2006) . Inflammation was also shown to affect the expression of other transporters in primary human hepatocytes (i.e. OATP1B1, OATP1B3, MDR1, MRP2) resulting in reduced mRNA expression, protein, and activity (Le Vee et al., 2011) . Thus, evidence exists to consider potential effects of underlying disease when interpreting age-related changes in transporter expression.
Finally, transporter genetic polymorphisms likely contribute to the observed variability in gene expression (DeGorter et al., 2012) . Recently, Nies et al and Prasad et al showed that hepatic expression of OATP1B1, but not OATP1B3, is significantly affected by genetic variants (Nies et al., 2013; Prasad et al., 2014) .
The observed age-dependent maturation and large inter-individual variability in drug transporter expression may have implications for oral drug absorption and hepatic drug excretion. The question whether posttranscriptional modifications occur and if expressed mRNA level can be extrapolated to protein expression and ultimately in vivo activity remains to be answered (Johnson et al., 2001; Fakhoury et al., 2005) . Human hepatic OATP1B1 and OATP1B3 protein expression showed a trend with high inter-individual variability in the first year of life followed by lower variability until the age of 8 years, when variability increases again (Thomson et al., 2013) . This typical age-related change in variability at younger age is 17 also reflected by our findings on OATP1B1 and OATP1B3 mRNA expression. In contrast, others could not correlate protein levels with OATP1B1 or MDR1 mRNA expression (Ulvestad et al., 2013) . Further protein expression and transporter activity studies are needed to confirm these mRNA expression results.
In conclusion, hepatic MDR1, MRP2, OATP1B1, OATP1B3 and intestinal MDR1, MRP2, OATP2B1 drug transporter expression show organ-and transporter-specific maturation patterns during childhood. Therefore, the disposition of drugs substrates for these transporters may be subject to age-related changes other than that in body size alone.
